ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

8.940 -0.060 (-0.67%)

Streaming Delayed Price Updated: 10:46 AM EDT, May 5, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	260,176
Open	9.010
Bid (Size)	8.930 (600)
Ask (Size)	8.950 (300)
Prev. Close	9.000
Today's Range	8.735 - 9.085
52wk Range	4.720 - 13.74
Shares Outstanding	122,816,314
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call

Today 1:34 EDT

NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performan...

Via StockStory

NEO Q1 Deep Dive: High-Value Test Expansion and Commercial Execution Drive Oncology Growth

April 29, 2026

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 11.1% ye...

Via StockStory

Performance

YTD	-24.0%	-24.0%
1 Month	+11.7%	+11.7%
3 Month	-27.4%	-27.4%
6 Month	-8.6%	-8.6%
1 Year	+16.1%	+16.1%

More News

NeoGenomics Inc (NASDAQ:NEO) Crushes Estimates on Robust Clinical Growth, Launches Novel MRD Test ↗

April 28, 2026

Via Chartmill

NeoGenomics (NEO) Q1 2026 Earnings Transcript ↗

April 28, 2026

Via The Motley Fool

NeoGenomics (NEO) Q1 2025 Earnings Transcript ↗

April 28, 2026

Via The Motley Fool

NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue

April 28, 2026

Via StockStory

NeoGenomics Reports First Quarter 2026 Results

April 28, 2026

From NeoGenomics, Inc.

Via Business Wire

NeoGenomics NEO Q2 2025 Earnings Transcript ↗

April 28, 2026

Via The Motley Fool

NeoGenomics Earnings: What To Look For From NEO

April 26, 2026

Via StockStory

Why NeoGenomics (NEO) Stock Is Trading Up Today

April 24, 2026

Via StockStory

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

April 23, 2026

From NeoGenomics, Inc.

Via Business Wire

2 Healthcare Stocks Worth Your Attention and 1 We Ignore

April 23, 2026

Via StockStory

NeoGenomics (NEO) Q4 2024 Earnings Transcript ↗

April 22, 2026

Via The Motley Fool

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

3 Unprofitable Stocks Walking a Fine Line

April 21, 2026

Via StockStory

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

April 13, 2026

From NeoGenomics, Inc.

Via Business Wire

A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack

April 12, 2026

Via StockStory

3 Cash-Burning Stocks We Think Twice About

April 08, 2026

Via StockStory

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

April 07, 2026

From NeoGenomics, Inc.

Via Business Wire

3 of Wall Street’s Favorite Stocks We Think Twice About

April 02, 2026

Via StockStory

2 High-Flying Stocks to Consider Right Now and 1 That Underwhelm

March 23, 2026

Via StockStory

NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

March 16, 2026

Via StockStory

NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

March 16, 2026

From NeoGenomics, Inc.

Via Business Wire

3 Reasons to Avoid NEO and 1 Stock to Buy Instead

February 25, 2026

Via StockStory

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

February 25, 2026

From NeoGenomics, Inc.

Via Business Wire

Frequently Asked Questions

Is NeoGenomics, Inc. - Common Stock publicly traded?

Yes, NeoGenomics, Inc. - Common Stock is publicly traded.

What exchange does NeoGenomics, Inc. - Common Stock trade on?

NeoGenomics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for NeoGenomics, Inc. - Common Stock?

The ticker symbol for NeoGenomics, Inc. - Common Stock is NEO on the Nasdaq Stock Market

What is the current price of NeoGenomics, Inc. - Common Stock?

The current price of NeoGenomics, Inc. - Common Stock is 8.940

When was NeoGenomics, Inc. - Common Stock last traded?

The last trade of NeoGenomics, Inc. - Common Stock was at 05/05/26 10:46 AM ET

What is the market capitalization of NeoGenomics, Inc. - Common Stock?

The market capitalization of NeoGenomics, Inc. - Common Stock is 1.10B

How many shares of NeoGenomics, Inc. - Common Stock are outstanding?

NeoGenomics, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.